Skip to content

Digestive and Nutritional Effects of Probiotics Supplementation in Premature Newborns

Digestive and Nutritional Effects of Probiotics (Bifidobacterium Longum and Lactobacillus GG) Supplementation in Premature Newborns

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00290576
Enrollment
127
Registered
2006-02-13
Start date
2004-04-30
Completion date
2008-06-30
Last updated
2008-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duration of Parenteral Nutrition

Keywords

Digestive and Nutritional Effects, Safety and Growth, Feeding Tolerance

Brief summary

Symbiotic interaction between probiotics (Living alimentary microbials supplemental, affecting positively host by improving intestinal microbial equilibrium (Fuller, 1989)) and human digestive tract was amply experimented and seems to be an interesting solution to orientate neonates digestive flora. Many studies showed a probant efficiency of probiotic supplementation in neonates on ECUN, despite abnormally high ECUN incidence in control group. Nevertheless, our aim is to test clinical efficiency of two new probiotics strains. Bifidobacterium Longum and Lactobacillus GG on Oral Nutrition (volume at Day 14 and Day 21) and safety (Adverse Events) in very premature babies.

Interventions

DIETARY_SUPPLEMENTProbiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
1 Days to 2 Weeks
Healthy volunteers
No

Inclusion criteria

1. newborns (\< 2 weeks of life) 2. 32 Weeks of Gestation, 3. weight \< 1500g, 4. Enteral nutrition begun, 5. Clinical stability, 6. Signed consent form from both parents.

Exclusion criteria

1. newborns (\>= 2 weeks of life), 2. weight \>= 1500g, 3. pathology avoiding the start of the enteral nutrition, 4. other pathologies of those due to premature and its complications, 5. No signed consent form.

Design outcomes

Primary

MeasureTime frame
Success if Patient reaches 50% of Nutritional needs by Enteral Nutritionat D14 and D21.

Secondary

MeasureTime frame
Age when Enteral Nutrition reaches 50% of Nutritional needs.
Incidence of Nosocomial Infections.
Composition of Colic Flora.
Fecal Calprotectin as Index of Inflammation

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026